Structure and function of somatostatin receptors in growth hormone control.
This new generation of SRIF analogs offer exciting opportunities to improve hormone hypersecretion in patients with GH- and TSH-secreting pituitary adenomas and possibly even in patients harboring prolactinomas and non-functioning tumors. Future development of novel analogs with improved affinity for both SSTR2 and SSTR5 may have even greater potency to suppress pituitary hormone hypersecretion and block adenoma growth.
Shimon
I
I
Department of Medicine, Cedars-Sinai Research Institute, UCLA School of Medicine 90048, USA.
Melmed
S
S
D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use; D002478:Cells, Cultured; D013006:Growth Hormone / Q000378:metabolism*; D006728:Hormones / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D015282:Octreotide / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000378:metabolism / Q000627:therapeutic use; D010902:Pituitary Gland / Q000196:embryology / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011485:Protein Binding; D017481:Receptors, Somatostatin / Q000502:physiology*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D006728:Hormones; D010456:Peptides, Cyclic; D017481:Receptors, Somatostatin; C060347:lanreotide; D013004:Somatostatin; D013006:Growth Hormone; D015282:Octreotide